Several of small-molecule STAT3 inhibitors, as well as other classes of agents, have been shown to be effective in targeting STAT3 and inhibiting tumor growth in preclinical models, including HNSCC, [33, 40]. The gene discussed is STAT3; the disease is neoplasm.